Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
TEMPORARY CLOSURE for Group C (Groups A1 and B Remain Open)
|Cancer Type:||High-Risk Neuroblastoma|
A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Age - Patient must be ≥ 365 Days and ≤ 30 Years of Age at Diagnosis.
ARM C perm closed
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Patients ≥ 1 year of age at the time of enrollment are eligible for this study.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.